An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)

Inclusion Criteria

• •Male and female adult (18 years or older) subjects for whom the treating physician has decided to start treatment with PegIntron® and Rebetol® and reaching the End-of-Treatment time point.
• •For the prospective component, evidence of treatment response at EOT after a complete course of therapy as per SmPC.
• •Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
• •Subjects must be diagnosed with chronic hepatitis C (genotypes 1, 2, 3, 4, 5 or 6).
• •Subjects must be free of any clinically significant disease that would interfere with study participation.